Management ChangeJul 13, 2026, 08:32 AM
Cue Biopharma Appoints Dominic Borie as Chief Medical Officer
AI Summary
Cue Biopharma, Inc. announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. Dr. Borie brings over two decades of experience in immunology and clinical development from leading biotechnology and pharmaceutical organizations. The company also reiterated its expectation for Phase 2 CSU data readout for CUE-221 by the end of Q3 2026 and the initiation of a Phase 1 clinical trial for CUE-401 by the end of Q4 2026, following a recent $50M private placement.
Key Highlights
- Dominic Borie appointed Chief Medical Officer and Head of Research & Development.
- Phase 2 CSU data readout for CUE-221 program expected by end of Q3 2026.
- Phase 1 clinical trial for CUE-401 on track to start by end of Q4 2026.
- Company recently secured a $50M private placement for clinical development.
- Dr. Borie received options for 63,000 shares and 31,500 restricted stock units.
Price Impact
More from CUE